Breaks Categories: News

WednesdayMar 26, 2025 10:32 am

NetworkNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Reports Encouraging Progress in Brain Cancer Trial with City of Hope

Calidi Biotherapeutics (NYSE American: CLDI) announced promising early results from a phase 1 clinical trial evaluating its CLD-101 investigational agent, a neural stem cell-based oncolytic virotherapy, in collaboration with City of Hope. The trial, targeting recurrent high-grade glioma, is the first to assess multiple weekly intracerebral doses of CLD-101. Fourteen participants have been treated so far with no safety concerns, and the study is now enrolling patients into the highest dosing cohort. The trial has expanded to Northwestern University and Stanford University, and is supported by a $12 million grant from the California Institute for Regenerative Medicine. Calidi retains licensing…

Continue Reading

WednesdayMar 26, 2025 10:21 am

NetworkNewsBreaks – Thumzup Media Corp. (NASDAQ: TZUP) Unveils Lifestyle AI Agent Marketplace and Files Trademarks for GibberAds 

Thumzup (NASDAQ: TZUP) announced the development of its patent-pending Lifestyle AI Agent Marketplace, a next-gen platform designed to deliver hyper-personalized experiences using specialized AI agents. The system will feature premium AI "swarms" that collaborate to create lifestyle plans in areas like travel, wellness, and entertainment, while offering real-time promotions to users from participating businesses. Thumzup also filed trademark applications for its AI-powered marketing tools, Gibberlink Advertising™ and GibberAds™, both of which will enable dynamic engagement between users, influencers, and advertisers. Monetization strategies include influencer affiliate programs, business AI accounts, and transaction-based commissions.  To view the full press release, visit https://nnw.fm/4yoWv …

Continue Reading

WednesdayMar 26, 2025 10:05 am

NetworkNewsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) Reports Record Revenue Surge Driven by Commercial EV Sales

Mullen Automotive (NASDAQ: MULN) announced record GAAP revenue of $3.18 million as of March 21, 2025, marking a 189% increase over its total 2024 revenue of $1.1 million. The surge reflects strong momentum in sales of its commercial EVs, including the Mullen ONE cargo van and Mullen THREE cab chassis truck, both of which are fully certified under U.S. emissions and safety standards. The company also highlighted progress from its Bollinger division, which began delivering its all-electric Class 4 B4 Chassis Cab truck in October. CEO David Michery stated the fiscal Q2 will close as the company’s strongest revenue quarter…

Continue Reading

TuesdayMar 25, 2025 1:20 pm

NetworkNewsBreaks – MoneyShow Event to Spotlight Insights for Navigating 2025 Market Dynamics 

MoneyShow, a premier producer of financial conferences for affluent investors, active traders, and financial advisors, has announced the return of Outlook 2025: Big Market Trends, Bold Investment Ideas. The two-day event, set to take place at the Hilton DFW Lakes in Dallas on Apr. 4-5, 2025, will provide actionable insights for navigating the opportunities and challenges of the new year. “Following the inauguration of President Trump, there has been increasing uncertainty and volatility in the markets. Investors are seeking answers about how important economic and political forces will influence their portfolios in 2025,” said MoneyShow’s Editor-in-Chief Mike Larson. “At this…

Continue Reading

TuesdayMar 25, 2025 11:03 am

NetworkNewsBreaks – SolarBank Corp. (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2) Closes $8.5 Million Direct Offering with Institutional Investor 

Disseminated on behalf of SolarBank Corporation  SolarBank (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2) has closed a registered direct offering with a single institutional investor, securing approximately $8.5 million in gross proceeds. The investor, backed by a bulge bracket investment bank and active in the energy sector, purchased 2,394,367 common shares and an equal number of warrants at a combined price of $3.55 per share. The warrants are immediately exercisable at $4.45 per share and expire in five years, potentially generating up to an additional $10.65 million. SolarBank plans to use the proceeds to support battery energy storage system projects,…

Continue Reading

TuesdayMar 25, 2025 10:43 am

NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports Phase 2 Results for Berubicin in Glioblastoma Trial 

CNS Pharmaceuticals (NASDAQ: CNSP) announced results from its Phase 2 clinical trial evaluating Berubicin for recurrent or progressive Glioblastoma Multiforme (GBM). While the study did not meet its primary endpoint of statistically significant improvement in overall survival compared to standard-of-care Lomustine, Berubicin showed comparable results across key clinical outcomes, including in patients with poor tumor markers. Importantly, no cardiotoxicity was observed, a major concern with other anthracyclines, and the safety profile remained favorable. The company plans to continue analysis and explore further development of Berubicin and its pipeline candidate TPI 287 for CNS malignancies.  To view the full press release,…

Continue Reading

TuesdayMar 25, 2025 9:57 am

NetworkNewsBreaks – Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) Hosts Investor Call Highlighting Actimab-A Clinical Progress and Expansion into Solid Tumors 

Actinium Pharmaceuticals (NYSE AMERICAN: ATNM), a leader in targeted radiotherapies, will hold an investor call today at 8:00 a.m. ET featuring Dr. Ehab Atallah, Professor of Medicine at the Medical College of Wisconsin and principal investigator of the Actimab-A + CLAG-M trial for relapsed/refractory acute myeloid leukemia (r/r AML). Dr. Atallah will present updated clinical results, including long-term survival data and plans for a pivotal Phase 2/3 trial under Actinium's cooperative research and development agreement ("CRADA") with the National Cancer Institute. Actinium's management will also discuss the launch of its Actimab-A solid tumor program, which includes trials combining Actimab-A with…

Continue Reading

TuesdayMar 25, 2025 9:30 am

NetworkNewsBreaks – Clene Inc. (NASDAQ: CLNN) to Present at Jones Las Vegas Technology and Innovation Conference

Clene (NASDAQ: CLNN), a clinical-stage biopharmaceutical company advancing treatments for neurodegenerative diseases such as ALS and MS, will participate in the Jones Las Vegas Technology and Innovation Conference on April 8–9, 2025. Held at The Venetian Resort, the event will feature one-on-one meetings, panels, and networking with institutional investors. Clene CEO Rob Etherington will represent the company as it continues to highlight progress across its therapeutic pipeline. The conference is hosted by JonesTrading with marketing support from B2i Digital, Inc. To view the full press release, visit https://nnw.fm/Nx11v About Clene Inc. Clene (along with its subsidiaries, “Clene”) and its wholly owned…

Continue Reading

TuesdayMar 25, 2025 9:20 am

NetworkNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Taps IBN to Lead Corporate Communications Strategy

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company targeting rare diseases, has selected IBN to manage its corporate communications and investor outreach. Soligenix is advancing late-stage clinical programs through its oncology and inflammation-focused Specialized BioTherapeutics segment and its Public Health Solutions division, which develops vaccines for biothreats such as ricin, Ebola, and Marburg. With support from roughly $60 million in non-dilutive funding and a pipeline that includes multiple orphan and fast-track designations, the company is preparing for potential regulatory approvals. IBN will amplify Soligenix’s message through its expansive media and investor network. To view the full article, visit https://nnw.fm/IOhxj About Soligenix…

Continue Reading

TuesdayMar 25, 2025 9:00 am

NetworkNewsBreaks – Centri Capital Conference to Showcase the Future of Capital Markets

Centri Business Consulting, LLC, one of the industry's fastest-growing and most respected accounting and advisory firms, is set to host its Centri Capital Conference. Slated to take place at Nasdaq in New York City on April 22, the event will bring together key players from the capital markets ecosystem, including investment bankers, private equity investors and venture capitalists. The conference will feature dynamic presentations from companies spanning rapidly growing sectors such as healthcare, life sciences and technology, as well as thought-provoking panel discussions on hot topics including blockchain, AI, IPO trends, and market disruptors. Designed as a platform for networking…

Continue Reading